Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Soft Tissue Infections 1Lymphoma, Follicular 1Infections 1Fournier Gangrene 1Fasciitis, Necrotizing 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Daptomycin × Lymphoid × Clear all
NCT00261807 2022-01-27

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

University of Maryland, Baltimore

Phase NA Completed
25 enrolled 7 charts
Lymphoid

Infections, Lymphoma, Follicular, Soft Tissue Infections, Fournier Gangrene, Fasciitis, Necrotizing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡